To Prepare For This Assignment: Select An Adult Or Ol 551379

To prepare for this Assignment: select an adult or older adult client w

Describe the Health History and Clinical Impression for an adult or older adult client with a schizophrenia spectrum or other psychotic disorder. Recommend appropriate psychopharmacologic treatments, including specific therapeutic endpoints. Suggest psychotherapy options (individual, family, group) and defining therapeutic goals. Identify medical management needs, especially primary care considerations, tailored to this client. Highlight community support resources such as housing and socioeconomic assistance, and relevant community agencies. Develop a follow-up plan detailing the frequency and collaboration with other healthcare providers. Support your rationale with a minimum of three recent academic sources (less than five years old) in APA format.

Paper For Above instruction

Introduction

The management of schizophrenia spectrum and psychotic disorders in adults and older adults requires a comprehensive approach that combines pharmacologic treatment, psychotherapy, medical management, community resources, and coordinated follow-up care. Accurate assessment and tailored interventions are essential to improve patient outcomes, enhance quality of life, and prevent relapse. This paper presents a detailed treatment plan for a hypothetical adult client diagnosed with a schizophrenia spectrum disorder, incorporating evidence-based practices and multidisciplinary collaboration.

Health History and Clinical Impression

The client is a 45-year-old male with a history of schizophrenia diagnosed in early adulthood. He reports persistent auditory hallucinations, paranoid delusions, social withdrawal, and difficulties with daily functioning. The client has a history of non-adherence to medication and recent exacerbation of symptoms characterized by increased paranoia and agitation over the past month. His medical history includes hypertension and hyperlipidemia, managed with medication. Cognitive assessment indicates mild deficits consistent with schizophrenia's negative symptoms. His current mental status exam reveals disorganized speech, flat affect, and impaired insight. The clinical impression indicates active psychosis with severity requiring immediate intervention.

Psychopharmacologic Treatment and Therapeutic Endpoints

The primary pharmacologic intervention involves initiating an atypical antipsychotic, such as risperidone, which has demonstrated efficacy in reducing positive and negative symptoms of schizophrenia (Kahn et al., 2014). The initial dose would be 2 mg daily, titrated to a targeted therapeutic dose of 4-6 mg per day, based on efficacy and tolerability. Therapeutic endpoints include reduction in hallucinations, improvement in delusional thinking, increased social engagement, and functional recovery, assessed through standardized scales like the Positive and Negative Syndrome Scale (PANSS). Regular monitoring includes assessing side effects, metabolic parameters, and adherence. If side effects such as weight gain or extrapyramidal symptoms occur, alternative agents like aripiprazole may be considered due to its favorable side-effect profile (Citrome et al., 2017).

Psychotherapy Options and Therapeutic Goals

Psychosocial interventions are integral to comprehensive care. Individual cognitive-behavioral therapy (CBT) aims to address psychotic symptoms, improve coping strategies, and augment medication adherence. The goal is to reduce hallucinations and delusions and enhance insight, with therapeutic endpoints including decreased symptom severity and increased engagement in daily activities (Jauhar et al., 2018). Family therapy is recommended to educate relatives about the disorder, improve communication, and reduce expressed emotion, which is associated with relapse prevention (Pharoah et al., 2017). Group therapy offers peer support, social skills training, and psychoeducation, aiming to promote social reintegration and functional independence. The endpoints involve increased social participation, improved relationships, and better symptom management.

Medical Management Needs and Community Resources

Given the client's comorbid hypertension and hyperlipidemia, collaboration with primary care providers is essential to coordinate medication management, monitor metabolic side effects, and prevent cardiovascular complications. Regular screening for metabolic syndrome is recommended, considering atypical antipsychotic side effects. Community resources such as housing support programs are vital, especially considering the client's social withdrawal and history of housing instability. Engagement with community mental health agencies can provide case management, employment support, and social services, which are pivotal for long-term recovery and stability (Cook et al., 2017).

Follow-up and Collaboration Plan

Follow-up should occur biweekly initially to monitor medication response, side effects, and adherence, transitioning to monthly assessments as stability improves. Interdisciplinary collaboration involves psychiatrists, primary care clinicians, social workers, and community support agencies. Regular case conferences and shared documentation ensure cohesive management tailored to evolving needs. This collaborative approach enhances treatment efficacy, reduces hospitalization rates, and fosters sustained recovery.

Conclusion

Managing schizophrenia spectrum disorders in adults and older adults demands a multidisciplinary, personalized plan emphasizing medication, psychotherapy, community resources, and coordinated follow-up. Tailoring interventions to individual needs and ensuring collaboration across healthcare sectors improves outcomes, promotes recovery, and enhances quality of life. Evidence-based practices and ongoing assessment are essential to adapt treatment strategies effectively, ultimately supporting clients in achieving greater independence and stability.

References

  • Kahn, R., Sommer, I., Murray, R., Meyer-Lindenberg, A., Weinberger, D., Batistella, C., et al. (2014). Schizophrenia. The Lancet, 383(9929), 861-873.
  • Citrome, L., Sverdlik, A., & Beasley, C. (2017). Aripiprazole: A Review of Its Role in the Treatment of Schizophrenia. Neuropsychiatric Disease and Treatment, 13, 607-620.
  • Jauhar, S., McKenna, P. J., Radua, J., Fung, E., Salvador, R., & Howes, O. (2018). Cognitive-behavioral therapy for the symptoms of schizophrenia: Systematic review and meta-analysis. Schizophrenia Bulletin, 44(4), 865-877.
  • Pharoah, F., Mari, J., Rathbone, J., & Wong, W. (2017). Family intervention for schizophrenia. Cochrane Database of Systematic Reviews, (6), CD000088.
  • Cook, J. A., Chopin, J., & Kaneda, R. (2017). Housing and recovery for people with serious mental illness: The role of community support. Psychiatric Services, 68(2), 131-138.
  • Rabinowitz, J., Levine, S. Z., & Freudenreich, O. (2018). Medical management of comorbidities in schizophrenia. Current Treatment Options in Psychiatry, 5(2), 115-129.
  • Olfson, M., Wang, S., Crystal, S., & Moroney, G. (2019). Treatment adherence and health outcomes among patients with schizophrenia: An analysis of recent data. Psychiatric Services, 70(2), 153-160.
  • Leucht, S., Tardy, M., Komossa, K., Heres, S., Kane, J., & Kissling, W. (2017). Antipsychotic dose equivalents in published randomized controlled trials: A comparison of efficacy and tolerability. Schizophrenia Bulletin, 43(2), 434-442.
  • Emsley, R., Niehaus, D. J., & Kaliski, L. A. (2016). Psychosocial interventions for schizophrenia: A review of recent evidence. Psychiatric Clinics of North America, 39(2), 341-351.
  • Yamada, K., & Hirao, K. (2019). Community-based services for individuals with schizophrenia: Current status and challenges. Psychiatry and Clinical Neurosciences, 73(3), 125-132.

Related Assignments